Patents by Inventor Alison M. Bendele

Alison M. Bendele has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Use of IL-1 inhibitors for treating IL-1 mediated diseases
    Publication number: 20090203609
    Abstract: The invention relates to methods for treating or preventing arthritis. The method comprises administering to patients in need thereof therapeutically effective amounts of an IL-1 inhibitor and methotrexate. In a preferred embodiment, the IL-1 inhibitor is human recombinant IL-1ra and the methotrexate is N-[4-[(2,4-diamino-6-pteridinyl)methylamino]benzoyl]-L-glutamic acid. The invention also relates to pharmaceutical compositions containing an IL-1 inhibitor and methotrexate useful in such methods.
    Type: Application
    Filed: February 27, 2009
    Publication date: August 13, 2009
    Inventors: Alison M. Bendele, Regina M. Sennello
  • Combination therapy using a TNF binding protein for treating TNF-mediated diseases
    Publication number: 20040047863
    Abstract: The invention relates to methods for treating or preventing acute and/or chronic arthritis. The method comprises administering to patients in need thereof therapeutically effective amounts of a TNF binding protein and methotrexate (N-[4-[[2,4-diamino-6-pteridinyl)methylamino]benzoyl]-L-glutamic acid). In a-preferred embodiment, the TNF binding protein is sTNFR-I or sTNFR-II. The invention also relates to pharmaceutical compositions containing a TNF binding protein and methotrexate useful in such methods.
    Type: Application
    Filed: July 16, 2003
    Publication date: March 11, 2004
    Applicant: Amgen Inc.
    Inventors: Alison M. Bendele, Regina M. Sennello, Carl K. Edwards
  • Combination therapy using a TNF binding protein for treating TNF-mediated diseases
    Publication number: 20040048799
    Abstract: The invention relates to methods for treating or preventing acute and/or chronic arthritis. The method comprises administering to patients in need thereof therapeutically effective amounts of a TNF binding protein and methotrexate (N-[4-[[2,4-diamino-6-pteridinyl)methylamino]benzoyl]-L-glutamic acid). In a preferred embodiment, the TNF binding protein is sTNFR-I or sTNFR-II. The invention also relates to pharmaceutical compositions containing a TNF binding protein and methotrexate useful in such methods.
    Type: Application
    Filed: July 16, 2003
    Publication date: March 11, 2004
    Applicant: Amgen Inc.
    Inventors: Alison M. Bendele, Regina M. Sennello, Carl K. Edwards
  • Use of II-1 inhibitors for treating II-1 mediated diseases
    Publication number: 20040044001
    Abstract: The invention relates to methods for treating or preventing arthritis. The method comprises administering to patients in need thereof therapeutically effective amounts of an IL-1 inhibitor and methotrexate. In a preferred embodiment, the IL-1 inhibitor is human recombinant IL-1ra and the methotrexate is N-[4-[(2,4-diamino-6-pteridinyl)methylamino]benzoyl]-L-glutamic acid. The invention also relates to pharmaceutical compositions containing an IL-1 inhibitor and methotrexate useful in such methods.
    Type: Application
    Filed: July 16, 2003
    Publication date: March 4, 2004
    Applicant: Amgen Inc.
    Inventors: Alison M. Bendele, Regina M. Sennello
  • Combination therapy using an IL-1 inhibitor and methotrexate
    Publication number: 20030072756
    Abstract: The invention relates to methods for treating or preventing arthritis. The method comprises administering to patients in need thereof therapeutically effective amounts of an IL-1 inhibitor and methotrexate. In a preferred embodiment, the IL-1 inhibitor is human recombinant IL-1ra and the methotrexate is N-[4-[(2,4-diamino-6-pteridinyl)methylamino]benzoyl]-L-glutamic acid. The invention also relates to pharmaceutical compositions containing an IL-1 inhibitor and methotrexate useful in such methods.
    Type: Application
    Filed: October 4, 2002
    Publication date: April 17, 2003
    Applicant: Amgen Inc.
    Inventors: Alison M. Bendele, Regina M. Sennello
  • Combination therapy using a TNF binding protein for treating TNF-mediated diseases
    Publication number: 20020119924
    Abstract: The invention relates to methods for treating or preventing acute and/or chronic arthritis. The method comprises administering to patients in need thereof therapeutically effective amounts of a TNF binding protein and methotrexate (N-[4-[[2,4-diamino-6-pteridinyl)methylamino]benzoyl]-L-glutamic acid). In a preferred embodiment, the TNF binding protein is sTNFR-I or sTNFR-II. The invention also relates to pharmaceutical compositions containing a TNF binding protein and methotrexate useful in such methods.
    Type: Application
    Filed: July 17, 2001
    Publication date: August 29, 2002
    Applicant: Amgen Inc.
    Inventors: Alison M. Bendele, Regina M. Sennello, Carl K. Edwards
  • Combination therapy using a TNF binding protein for treating TNF-mediated diseases
    Patent number: 6306820
    Abstract: The invention relates to methods for treating or preventing acute and/or septic shock. The method comprises administering to patients in need thereof therapeutically effective amounts of a TNF binding protein and a Fas antigen. In a preferred embodiment, the TNF binding protein is sTNFR-I or sTNFR-II. The invention also relates to pharmaceutical compositions containing a TNF binding protein and a Fas antigen useful in such methods.
    Type: Grant
    Filed: June 4, 1999
    Date of Patent: October 23, 2001
    Assignee: Amgen Inc.
    Inventors: Alison M. Bendele, Regina M. Sennello, Carl K. Edwards III
  • Method of treating inflammation
    Patent number: 5416090
    Abstract: The present invention relates to the use of certain ergoline analogues and BCD tricyclic ergoline part-structure analogues as defined herein as anti-inflammatory agents.
    Type: Grant
    Filed: December 8, 1992
    Date of Patent: May 16, 1995
    Assignee: Eli Lilly and Company
    Inventors: Alison M. Bendele, Henry U. Bryant, John M. Schaus